Novo Nordisk.
company in Rome, Italy
- Reports this week
- 2
- Active events
- 2
- Connections
- 18
What's happening
Active this week
-
Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.Some support1 report
-
Novo Nordisk operates in Europe, Africa, North America, the Middle East, Hong Kong, and mainland China.Some support3 reports1 development inside
One to three months ago
-
Eli Lilly and Novo Nordisk are seeking regulatory approval for the CagriSema candidate, facing competitive challenges regarding clinical efficacy.Some support2 reports
-
Donald Trump struck a deal with Novo Nordisk and Eli Lilly and Company to cut drug prices.Some support1 report1 development inside
-
A settlement focusing on TrumpRx is underway, requiring curbing rebate use and including payments from Eli Lilly and Novo Nordisk's popular weight-loss drugs.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Novo Nordisk this week
News at the entities that move Novo Nordisk most-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Novo Nordisk
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Novo Nordisk
-
Donald Trump OperationalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Novo Nordisk
-
Europe OperationalThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Novo Nordisk
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Novo Nordisk
-
Cramer Mentioned togetherCramer advises viewers to buy GEV shares, noting that the company benefits from Trump tariffs and onshoring.Moves Novo Nordisk
Connections
The 15 strongest of 18, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Eli Lilly and Company Operational
The two companies are direct, high-stakes competitors in the global weight loss and diabetes drug markets, evidenced by market rivalry and active litigation.
-
Food and Drug Administration Structural
Novo Nordisk's products are subject to the mandatory review and approval process of the Food and Drug Administration.
-
FDA Structural
Novo Nordisk is seeking regulatory approval from the FDA for its CagriSema candidate, establishing a functional dependency for market access.
-
Johnson & Johnson Operational
The two companies are actively engaged in competition within the pharmaceutical market.
-
Donald Trump Operational
Donald Trump's TrumpRx initiative focuses on utilizing weight-loss drugs from Novo Nordisk following a drug price deal.
-
Europe Operational
Novo Nordisk conducts business operations within the European market bloc.
-
Cosmo Operational
The two companies actively compete within the drug and treatment market.
-
Nvidia Mentioned together
Both companies are mentioned in market signals comparing past company performance.
Show all 15 connections
-
Africa Shared context
Novo Nordisk conducts business operations within the geographical and market context of Africa.
-
Cramer Mentioned together
Cramer provided market commentary suggesting Novo Nordisk competes in the market.
-
mainland China Shared context
Novo Nordisk conducts business operations within the geographical and market context of mainland China.
-
Hong Kong Shared context
Novo Nordisk is reported to operate within the jurisdiction of Hong Kong.
-
North America Shared context
Novo Nordisk operates within the geographical and market context of North America.
-
Middle East Shared context
Novo Nordisk is reported to operate within the geographical context of the Middle East.
-
Venky Soundararajan Mentioned together
The single snapshot describes the person's founding of a company but does not establish a direct relationship with Novo Nordisk.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
2 eventsJuly 2026
2 events- Eli Lilly and Novo Nordisk are seeking regulatory approval for the CagriSema candidate, facing competitive challenges regarding clinical efficacy.
- A settlement focusing on TrumpRx is underway, requiring curbing rebate use and including payments from Eli Lilly and Novo Nordisk's popular weight-loss drugs.